Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123853 | 0.92 | ROCK2 (0.51) | CNR1KMT2APOLBMAPTROCK2 | |
| SCHEMBL3929530 | 0.87 | CNR1 (0.52) | CNR1HTTKMT2APOLBMAPT | |
| SCHEMBL1229210 | 0.79 | ROCK2 (0.51) | KMT2APOLBTDP1ROCK2MEN1 | |
| SCHEMBL3933572 | 0.79 | ROCK2 (0.49) | CNR1KMT2APOLBMAPTROCK2 | |
| SCHEMBL12907088 | 0.78 | MEN1 (0.52) | KMT2APOLBMEN1NPC1RAB9A | |
| SCHEMBL4116438 | 0.77 | CNR1 (0.61) | CNR1HTTKMT2APOLBMAPT | |
| SCHEMBL922192 | 0.76 | ANO1 (0.46) | — | |
| SCHEMBL4116192 | 0.75 | CNR1 (0.47) | CNR1HTTKMT2AMEN1 | |
| SCHEMBL4119234 | 0.74 | KMT2A (0.41) | KMT2AROCK2PKMRAB9A | |
| SCHEMBL28411219 | 0.72 | CNR1 (0.69) | CNR1HTTKMT2APOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | CNR1 2880/4885HTT 3713/4885KMT2A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.